Subscribe to our Newsletters !!
Few developments in science and technology have be
In laboratories where precision is key, like pharm
The recent rabies death of an 11 year old Canadian
Alembic Pharmaceutica
Generic medicines have become a cornerstone in hea
Tofu used to be associated with Asian cuisine, but
Dear Readers, Welcome to the latest issue of Mi
26th December, 2022, Mumbai: Alembic Pharmaceuticals Limited (Alembic) today announced that it has received final approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA), Fulvestrant Injection, 250 mg/5 mL (50 mg/mL) per Single-Dose Prefilled Syringe. The approved ANDA is therapeutically equivalent to the reference listed drug product (RLD), Faslodex Injection, 250 mg/5 mL (50 mg/mL), of AstraZeneca Pharmaceuticals LP. Fulvestrant Injection is an estrogen receptor antagonist indicated for the treatment of breast cancer. Refer to our label for full indication.
Fulvestrant Injection, 250 mg/5 mL, has an estimated market size of US$71 million for twelve months ending Sep 2022 according to IQVIA.
Alembic has received a cumulative total of 179 ANDA approvals (156 final approvals and 23 tentative approvals) from USFDA.
